Clinical trials: Sunitinib
GIST
To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.
To compare the efficacy of surgery followed by sunitinib with surgery followed by imatinib in GIST patients with progression on imatinib;To investigate the optimal therapy after surgery in GIST patients with focal or multifocal…
- Trial name
- NCT03424876
- Testing
- Imatinib 400mg, Sunitinib 37.5Mg Oral Capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University
GIST, Malignant, KIT Exon 13 Mutation
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST
This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and/or unresectable GIST after prior failure or intolerability of imatinib.
- Conditions
- GIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation
- Trial name
- POETIG (NCT03171389)
- Testing
- Ponatinib 30 MG
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Sebastian Bauer
Liver Cancer
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
An open label multi-site phase II clinical trial of dose escalated sunitinib malate given orally once daily on days 1-28 of each 42-day cycle.
- Trial name
- NCT00495625
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ebola Virus Disease
Multiple Treatments for Ebola Virus Disease (EVD)
The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)
- Trial name
- NCT02380625
- Testing
- Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan
- Volunteers
- 150 people
- Sponsor
- Clinical Research Management, Inc.
Thymic Carcinoma
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to…
- Trial name
- NCT03463460
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dwight Owen
Cancer, Oral Drug Administration
Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.
This is a prospective testing-validation, interventional, non-pharmacological study on a new app for oral anticancer therapy management.
- Trial name
- NCT02921724
- Testing
- TreC-Onco
- Where
- 3 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
GIST
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
- Trial name
- NCT01459757
- Testing
- non-interventional
- Where
- 36 sites in United States, Australia and 14 more
- Volunteers
- 322 people
- Sponsor
- Pfizer
Clear-cell Renal Cell Carcinoma, RCC
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms.
- Conditions
- Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
- Trial name
- NCT03035630
- Testing
- Avelumab, Sunitinib
- Where
- United States
- Sponsor
- Guru Sonpavde
Renal Cell Carcinoma
Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT06032728
- Testing
- Sunitinib
- Volunteers
- 488 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in treating patients with pancreatic cancer or other solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00462553
- Testing
- sunitinib malate, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Molecular Determinants for Therapy Response on Renal Cell Carcinoma
Aim of the scientific analysis is to find biological factors (biomarkers) allowing a prediction of disease progression and a better choice of therapy.
- Trial name
- MORE (NCT02208128)
- Testing
- Sunitinib, Pazopanib, Bevacizumab, Everolimus...
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Heidelberg University
Renal Cell Carcinoma, Kidney Cancer
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
The purpose of this study is to test the safety of RAD-001 and Sunitinib given in combination for renal cell cancer. We also want to find out what effects (good and bad) the combination of RAD-001 and Sunitinib have on you and…
- Trial name
- NCT00422344
- Testing
- RAD001, Sunitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with…
- Trial name
- NCT00113516
- Testing
- carboplatin, paclitaxel, sunitinib
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Advanced Biliary Tract Adenocarcinoma
Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
- Trial name
- NCT01082809
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Samsung Medical Center
Unresectable or Metastatic Colorectal Cancer
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
- Trial name
- NCT00668863
- Testing
- FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil), Sunitinib
- Where
- 10 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before.
- Trial name
- SUNIKA (NCT00460798)
- Testing
- Sutent: observational study
- Volunteers
- 356 people
- Sponsor
- Pfizer
Solid Tumor
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
The safety and tolerability of CVX-060 have been established in the first-in-human clinical trial, CVX-060-101. Thus, this phase Ib/II trial is to assess the safety and pharmacokinetics (PK) profiles of combining CVX-060 with…
- Trial name
- NCT00982657
- Testing
- CVX-060 + sunitinib, Sunitinib
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Colorectal Cancer, Metastatic Cancer
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00936832
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- France
- Sponsor
- Federation Francophone de Cancerologie Digestive
Clear Cell Renal Carcinoma
TroVax Renal Immunotherapy Survival Trial
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
- Trial name
- NCT00397345
- Testing
- Trovax, Standard of care therapy
- Where
- 152 sites in United States, France and 8 more
- Volunteers
- 733 people
- Sponsor
- Oxford BioMedica
Genitourinary Disease
Sunitinib Malate in Refractory Germ Cell Tumors
The goal of this clinical research study is to learn if Sutent® (sunitinib malate, SU011248) can control the disease in patients with germ cell tumors that are resistant to earlier treatment.
- Trial name
- NCT00912912
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center